Defining a therapeutic window for kinase inhibitors in leukemia to avoid neutropenia

Neutropenia represents one of the major dose-limiting toxicities of many current cancer therapies. To circumvent the off-target effects of cytotoxic chemotherapeutics, kinase inhibitors are increasingly being used as an adjunct therapy to target leukemia. In this study, we conducted a screen of leuk...

Descripción completa

Detalles Bibliográficos
Autores principales: McArthur, Kate, D’Cruz, Akshay A., Segal, David, Lackovic, Kurt, Wilks, Andrew F., O’Donnell, Joanne A., Nowell, Cameron J., Gerlic, Motti, Huang, David C.S., Burns, Christopher J., Croker, Ben A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Priority Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601625/
https://www.ncbi.nlm.nih.gov/pubmed/28938529
http://dx.doi.org/10.18632/oncotarget.19678

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601625/
https://www.ncbi.nlm.nih.gov/pubmed/28938529
http://dx.doi.org/10.18632/oncotarget.19678

Ejemplares similares